[Federal Register Volume 62, Number 165 (Tuesday, August 26, 1997)]
[Notices]
[Pages 45272-45273]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 97-22564]


-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration


Manufacturer of Controlled Substances; Notice of Application

    Pursuant to Section 1301.33 of Title 21 of the Code of Federal 
Regulations (CFR), this is notice that on July 10, 1997, Novartis 
Pharmaceutical Corp., 59 Route 10, East Hanover, New Jersey 07936, made 
application by letter dated July 10, 1997, to the Drug Enforcement 
Administration (DEA) for registration as a bulk manufacturer of the 
Schedule II controlled substance methylphenidate (1724).
    The firm, which is currently registered with DEA as a bulk 
manufacturer of methylphenidate at another location plans to 
manufacture validation batches in preparation of

[[Page 45273]]

moving all bulk manufacturing of methylphenidate to the above location.
    Any other such applicant and any person who is presently registered 
with DEA to manufacture such substances may file comments or objections 
to the issuance of the proposed registration.
    Any such comments, or objections may be addressed, in 
quintuplicate, to the Deputy Assistant Administrator, Office of 
Diversion Control, Drug Enforcement Administration, United States 
Department of Justice, Washington, D.C. 20537, Attention: DEA Federal 
Register Representative (CCR), and must be filed no later than (60 days 
from publication).

    Dated: July 29, 1997.
John H. King,
Deputy Assistant Administrator, Office of Diversion Control, Drug 
Enforcement Administration.
[FR Doc. 97-22564 Filed 8-25-97; 8:45 am]
BILLING CODE 4410-09-M